Iron, one of the essential element, plays an important role in biological processes such as the synthesis of heme, energy metabolism, neurotransmitter production, formation of myoglobin, formation of collagen, and immune system function. Deficiency of iron is one of the major causes of iron deficiency anemia (IDA) associated with increased morbidity and mortality. According to a survey conducted by the Vitamin and Mineral Nutrition Information System in 2017, around 30% of anemia in women and children in developing countries is due to iron deficiency. In the 19th century, Pierre Blaud introduced ferrous sulfate which became the standard treatment for IDA.
Iron supplements are available in two forms: oral and intravenous. Intravenous iron preparations are superior to oral supplements, as these lead to higher and faster increase in iron and Hb levels. Oral supplements have disadvantages such as GI adverse events, poor adherence, poor gastrointestinal absorption, and non-compliance.
Major drivers of the IV iron drugs market are increase in incidence of iron deficiency, rise in chronic kidney disease patients undergoing dialysis, and surging diabetic population. Increase in iron deficiency anemia in gynecology, oncology, and gastroenterology, noncompliance of oral therapy, and accurate, easy, and convenient access to IV iron dosages drive demand for intravenous iron drugs. However, complex approval process, stringent regulations, drug side effects, nutraceutical alternatives to prevent iron deficiency, and product price are likely to act as major restraints of the IV iron drugs market.
The IV iron drugs market has been segmented based on product type and therapeutic area. Product types are ferric gluconate, ferric carboxyl maltose, iron sucrose, and iron dextran. Ferric gluconate accounts for the largest market share of the IV iron drugs market as it is one of the most effective forms of treatment of iron-deficiency anemia. However, at present, there is no data comparing it to existing preparations but it is expected to grow relatively faster due to the superior performance and increasing application. Based on therapeutic use, the IV iron drugs market has been divided into oncology, nephrology, gynecology, gastroenterology, heart failures, and surgeries. Increased usage of IV iron drugs among chronic kidney disease patients has led to the nephrology segment capturing the largest market share. Chronic Heart Failure is expected to be the fastest growing segment owing to rise in number of patients with heart related disorders.
In terms of region, the intravenous iron drugs market has been segmented into North America, Europe, Asia Pacific, Middle East & Africa, and Latin America. North America accounts for the major market share owing to rise in use of intravenous iron drugs in oncology. The market in emerging countries such as India and China in Asia Pacific is expected witness strong growth due to increasing investment by governments and private companies in biotechnology and biopharmaceutical industry, growing investment opportunities in developing countries, increase in diagnostic laboratories, and rise in prevalence of IDA among women in the developing countries. The intravenous iron drugs market is competitive, owing to emergence of new entrants in the market and presence of well-established firms.
Key players in the intravenous iron drugs market are Allergan, Inc., AMAG Pharmaceuticals. Inc., Galenica Ltd., Actavis, Inc., American Regent. Inc., Sanofi, Luitpold Pharmaceuticals, Inc., Fresenius Medical Care AG & Co., Pharmacosmos A/S, and Vifor Pharma Ltd.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
- Market segments and sub-segments
- Market trends and dynamics
- Supply and demand
- Market size
- Current trends/opportunities/challenges
- Competitive landscape
- Technological breakthroughs
- Value chain and stakeholder analysis
The regional analysis covers:
- North America (U.S. and Canada)
- Latin America (Mexico, Brazil, Peru, Chile, and others)
- Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
- Eastern Europe (Poland and Russia)
- Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
- Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report:
- A complete backdrop analysis, which includes an assessment of the parent market
- Important changes in market dynamics
- Market segmentation up to the second or third level
- Historical, current, and projected size of the market from the standpoint of both value and volume
- Reporting and evaluation of recent industry developments
- Market shares and strategies of key players
- Emerging niche segments and regional markets
- An objective assessment of the trajectory of the market
- Recommendations to companies for strengthening their foothold in the market
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.